TWI334350B - Cancer treatment - Google Patents
Cancer treatment Download PDFInfo
- Publication number
- TWI334350B TWI334350B TW091102797A TW91102797A TWI334350B TW I334350 B TWI334350 B TW I334350B TW 091102797 A TW091102797 A TW 091102797A TW 91102797 A TW91102797 A TW 91102797A TW I334350 B TWI334350 B TW I334350B
- Authority
- TW
- Taiwan
- Prior art keywords
- tumors
- inhibitor
- tumor
- compound
- rapamycin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 74
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims description 17
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 17
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 83
- 229960002930 sirolimus Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 230000008482 dysregulation Effects 0.000 claims description 10
- -1 ketokonazole Chemical compound 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- 239000012752 auxiliary agent Substances 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 108091008606 PDGF receptors Proteins 0.000 claims description 7
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 239000003886 aromatase inhibitor Substances 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 3
- 229940122964 Deacetylase inhibitor Drugs 0.000 claims description 3
- 102000003964 Histone deacetylase Human genes 0.000 claims description 3
- 108090000353 Histone deacetylase Proteins 0.000 claims description 3
- 102000029749 Microtubule Human genes 0.000 claims description 3
- 108091022875 Microtubule Proteins 0.000 claims description 3
- 206010029098 Neoplasm skin Diseases 0.000 claims description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 3
- 229950004810 atamestane Drugs 0.000 claims description 3
- 210000000013 bile duct Anatomy 0.000 claims description 3
- 230000009400 cancer invasion Effects 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- 229960004421 formestane Drugs 0.000 claims description 3
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims description 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims description 3
- 210000004688 microtubule Anatomy 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 claims description 3
- 229960005353 testolactone Drugs 0.000 claims description 3
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 claims description 3
- 229960001670 trilostane Drugs 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229940122588 Heparanase inhibitor Drugs 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 230000009949 anti-apoptotic pathway Effects 0.000 claims description 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims description 2
- 230000008512 biological response Effects 0.000 claims description 2
- 150000004663 bisphosphonates Chemical class 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 210000000959 ear middle Anatomy 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000000578 peripheral nerve Anatomy 0.000 claims description 2
- 150000003058 platinum compounds Chemical class 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 210000003445 biliary tract Anatomy 0.000 claims 2
- 229950011548 fadrozole Drugs 0.000 claims 2
- 229960001771 vorozole Drugs 0.000 claims 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 102400000967 Bradykinin Human genes 0.000 claims 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 229940091658 arsenic Drugs 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 229950008745 losoxantrone Drugs 0.000 claims 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 206010061311 nervous system neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 229940035936 ubiquinone Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract description 21
- 241000282412 Homo Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 229940126062 Compound A Drugs 0.000 description 14
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 9
- 229960000235 temsirolimus Drugs 0.000 description 9
- 229950009819 zotarolimus Drugs 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 5
- 201000005787 hematologic cancer Diseases 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 4
- 108090000315 Protein Kinase C Proteins 0.000 description 4
- 102000003923 Protein Kinase C Human genes 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 108010017796 epoxidase Proteins 0.000 description 2
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- YJZSUCFGHXQWDM-UHFFFAOYSA-N 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate Chemical compound OC1=CC=C(O)C(CNC=2C=CC(=CC=2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1 YJZSUCFGHXQWDM-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- OCYJXSUPZMNXEN-UHFFFAOYSA-N 2-amino-1-(4-nitrophenyl)propane-1,3-diol Chemical compound OCC(N)C(O)C1=CC=C([N+]([O-])=O)C=C1 OCYJXSUPZMNXEN-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- VPNXKXUNASBBLU-UHFFFAOYSA-N 6-ethyl-5-[3-(3,4,5-trimethoxyphenyl)prop-1-ynyl]pyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C#CCC1=CC(OC)=C(OC)C(OC)=C1 VPNXKXUNASBBLU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229940119334 Chymase inhibitor Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 229940123917 Lipid kinase inhibitor Drugs 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- PDNNQADNLPRFPG-UHFFFAOYSA-N N.[O] Chemical compound N.[O] PDNNQADNLPRFPG-UHFFFAOYSA-N 0.000 description 1
- GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- MBJMCOJMDMARNB-UHFFFAOYSA-N O.O.O.O.[Na].[Na].OP(O)(=O)C(Cl)(Cl)P(O)(O)=O Chemical compound O.O.O.O.[Na].[Na].OP(O)(=O)C(Cl)(Cl)P(O)(O)=O MBJMCOJMDMARNB-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108091033399 Telomestatin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- UWIJQSUOVPFKBY-UHFFFAOYSA-N [Pt].N.[C] Chemical compound [Pt].N.[C] UWIJQSUOVPFKBY-UHFFFAOYSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XKUTVNLXHINPAP-UHFFFAOYSA-N azane platinum Chemical compound N.[Pt] XKUTVNLXHINPAP-UHFFFAOYSA-N 0.000 description 1
- 229930195545 bengamide Natural products 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- JIKADBNXDMHWFV-UHFFFAOYSA-N carbamimidoylazanium;formate Chemical compound [O-]C=O.NC([NH3+])=N JIKADBNXDMHWFV-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003601 chymase inhibitor Substances 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000003458 notochord Anatomy 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000003065 pyriform sinus Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Description
1334350 A7 ' B7 , -;_S- 五、發明説明(、) 本發明有關一種新穎用途,尤其是包括雷帕黴素 (rapamycin)及其衍生物之化合物%群之新穎用途。 雷帕黴素為由鏈黴菌吸濕所產生之一種已知大環内脂族 抗生素。雷帕徵素之適宜衍生物包含例如式I之化合物:
其中 .Ri為CH3或C3-6块基, R2為 Η或-CH2-CH2-OH,及 X為=0、(Η,Η)或(H,OH) 菩條件為當X為=0及Ri為CH3時,R2不為Η。 式I化合物係揭示於例如WO 94/09010、WO 95/1669 1或 WO 96M1807,其併於本文供參考。其可如該等參考文獻 所揭示般或藉其類似程序製備。 較佳化合物為32-去氧雷帕黴素、16-戊-2-炔基氧基-32-去氧雷帕黴素、16-戊-2-块基氧基-32(S)-二氫-雷帕黴素、 16-戊-2-块;ί氧基-3 2(S)-二氫-40-0-(2-羥基乙基)-雷帕黴 素,且更好為40-0-(2-羥基乙基)-雷帕黴素(後文稱為化合 物A),如WO 94/090 10實例8所述。 -5- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1334350 A7 ' B7 五、發明説明(2 ) 依據所觀察之活性例如結合至巨唆細胞素(macrophilin)-12 (亦稱為FK-506結合蛋白質或FKBP- 12)之活性(例如W〇 ^4/09010 ' W0 95/1669 1 或 WO 96/4 1807所述)已發現可在例 如冷療急性異體移植排斥中作為例如免疫抑制劑。如今發 現式I化合物具有強力、抗增殖性質,使其可用於癌症之化 學療法,尤其是用於實心腫瘤,特別是末期實心腫瘤。因 此仍需要增設實心腫瘤之癌症治療醫療設備,尤其是當以 _-抗癌症化合物治療無法使疾病復原或穩定之情況。 依據本發明特定發現,係提供: 1.1 一種對需要之個體治療實心腫瘤之孝法.,包括對該個 體投與治療有效量之式I化合物。 1.2 一種對需要之個體抑制實心腫瘤生長之方法,包括對 該個體投與治療有效量之式I化合物。 1.3 一種於需要之個體誘腫瘤退化例如使腫瘤塊減小之方 法,包接對該個體投與治療有效量之式I化合物。 _ 1.4 一種對需要之個體治療與腫瘤成長有關之實心腫瘤侵 入或病徵之方法,包括對該個體投與治療有效量之式 I化合物。 1.5 —種對需要之個體預防腫瘤遷移擴大或預防或抑制微 遷移成長之方法,包括對該個體投與治療有效量之式 I化合物。 "實心腫瘤"意指非淋巴癌之腫瘤及/或遷移(無論何 _ 處),例_如腦及其他中樞神經系統腫瘤(例如腦膜、腦、脊 索、頭蓋神經及中樞神經系統之其他部分之腫瘤,例如神 -6- 本纸浪尺度適用中國國家標準(CNS) A4規格(21〇x 297公釐)
装 訂 1334350
經母細胞瘤或脊髓胚細胞瘤);頭及/或頸之癌症;***腫 瘤i循環系統腫瘤(例如心臟、縱隔膜及肋膜及其他腦脊 ml膜内器g ,血管腫瘤及與腫瘤相關之血管組織);*** 系統之腫瘤(例如腎臟、腎臟骨盆、膀胱、其他及非特定 之泌尿器官);腸胃道腫瘤(例如食道、冒、小腸、結腸、 結直腸、乙狀結直腸接何處、直腸、肛門及肛門道);包 含肝臟及内部膽汁導管、膽囊、其他及未特定部分之膽二 运、胰、其他及消化性器官之腫瘤;頭及頸;口腔(唇、 舌牙齦、角底、上顎、及嘴部其他部分、腮腺及唾液線 之其他部分、扁桃腺、咽口、鼻咽、梨狀竇、咽下部及唇 之其他部位,口腔及咽頭);再生系統之腫瘤(例如***、 陰運、子:頸、子:體、子宮、卵巢、及女性生殖器官其 他部位、胎盤、陰莖、***、睪丸、及***官之 其他部位);呼吸道腫瘤(例如鼻腔及中耳,副竇 '喉頭' 氣管、支氣_爹及肺,例如小細胞肺癌或非小细胞肺癌);_ 骨路系統腫瘤(例如臀部之骨愁及關節軟骨、骨路關節軟 骨及其他部位);也膚腫瘤(例如皮膚之惡性黑色瘤、非黑 I瘤皮膚癌、皮膚之基礎細胞癌瘤、皮膚之鱗狀細胞癌' 瘤、間皮瘤、卡波希氏(Kaposi’s)肉瘤);及包含其他組織 之腫瘤,包含末梢神經及自主神經系統、結缔及軟骨組 織、後腹腔及腹腔、眼晴及附件、甲狀腺、腎上腺及其他 内分泌腺及相關之結構、淋巴結之第二種及未特定之朵性 -腫瘤、.呼吸及消化系統之第二種及惡性腫瘤、及其他部位 之第二種惡性腫瘤。
裝 本紙張尺度適用中國國家標準(CNS) A4规格(210X297公发) 1334350 A7 ' B7 五、發明説明(4 ) 前述及後續提及之腫瘤、腫瘤疾病、癌瘤或癌症(以及 包含原器官或組織及/或其他位置中之遷移)係另外或其他 暗示包含任何腫瘤位置及/或移轉。依又另外特定或其他 具體例,本發明亦提供: 1.6 一種對需要之個體治療與血管形成失調有關之疾病之 方法,包括對該個體投與治療有效量之雷帕黴素或其 衍生物,例如CC1779、ABT578或一式I之化合物。 」 1.7 —種對需要之個體抑制或控制血管形成失調之方法, 包括對該個體投與治療有效量之雷帕黴素或其衍生 物,合士aCCI779、ABT578 或一式 14匕合物。 1.8 一種對需要之個體增進化學治療藥劑活性或克服對化 學治療藥劑抗性之方法,包括對該個體同時或依序投 與該化學治療藥劑及治療有效量之雷帕黴素或其衍生 物,例如CCI779、ABT578或·一式I化合物。 1.9 依據1.8_之方法,其中化學治療藥劑為直接抗宿主細 一 胞或涉及腫瘤形成及/或遷移形成有關之過程或藉腫 瘤細胞而供藥物抗性之增殖、存活、·分化或發展所利 用之過程中之訊號傳導路徑之抑制劑,。 1. 10如上述之方法,其中雷帕黴素或其衍生物,例如 CCI779、ABT5 78或一式I化合物係間歇性投藥。 CC 1779為雷帕黴素衍生物,亦及40-[3-羥基-2-(羥基甲 基)-2-甲基丙_酸酯]-雷帕黴素或其醫藥可接受性鹽,且係 . 揭示於例如USP 5,3 62,718。ABT578為又包括二烯還原之 40-取代之雷帕激素衍生物。 -8- 本紙浪尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
裝 訂 1334350 五 發明説明( A7 B7 與血管形成失調有關之疾病實例包含(但不限)例如赞瘤 疾病’例如實心腫瘤。血管形成代表會生長超出某直徑例 如約丨-2毫米之該等腫瘤之必要條件。 系列其他特太或另外具體例,本發明亦提供: -.1種式1化合物,係用於上述1.丨至1.5定義之任一種方 法之用途。 2.2雷帕黴素或其衍生物’例如ccm9、或一式^ 化δ物,其係用於上述丨6至11〇或下述7定義之任一 方法。 31 一種式1之化合物,係用於製備上述1.1至1.5定義之任 一方法中所用之醫藥組合物。 乂2雷帕黴素或其衍生物,如CCI779、ΑΒΤ578或一式I化 合物,係用於製備上迷1.6至1.10或下述7中定義之任 一方法中所用之醫藥組合物。 41 一種用於上述11至h5定義之任一方法之醫藥組合 物,包括一式I化合物及一或多種醫藥可接受性稀釋 劑或載體。 42 一種用於上述h6至1·10或下述7中定義之任一方法之 醫藥組合物’包括雷帕黴素或其衍生物如CCI779、 ABT578或一式I化合物例如化合物a及一或多種醫藥 可接受性稀釋劑或載體。 51 一種醫藥結合劑’包括a)雷帕黴素或其衍生物,如 CCI7?9、-· ABT578或一式I化合物如化合物a之第一種 藥劑’及b)化學治療藥劑之赞劑,例如後文定義者。 -9- 本纸張&度適用中國國家標準(CNS> A4規格(21〇 X 297公爱) 1334350 五、發明説明(6 6 · 一種醫樂組合物,包括某量之a)雷帕徵素或其衍生 物,如CCI779、ABT578或—式丨化合物如化合物八之 第-種藥劑’及b)選自以下(1V)或⑺段落定義之化合 物之化學治療藥劑之輔劑,而產生協同治療作用。 一種如上定義之方法’包括共投與(同時或依序)例如 治療有效量之雷帕黴素或其衍生物,如cci779、 A B T 5 7 8或-式!化合物例如化合物A,及第二種藥物 物質’菽第二種藥物物質為化學治療劑,例如以下定 義者。 7. 一種對需要之個體治療移柏铭从p+ .夕植後淋巴増殖性失調或淋巴 癌之方法’例如治療與腫痧忐 心成長有關 < 腫瘤侵入或病 徵之方法’包括對該個體丑 豆/、投與(同時或依序)例如治 療有效量之雷帕黴素4並彡〜 乂具何生物,例如CCI779、 ABT5 78或一式I化合物例如 丨J如化合物A,及第二種藥物 物質,窣第二種藥物物質為 貝A化學治療劑,例如以下定 義者。 ”淋巴癌j —司意指例如血液戎,u於, 、, 一设或淋巴系統腫瘤(例如亨丁 頓(Hodgkin’s)症、非亨丁頓淋巴痂 β、柏奇特(Burkitt’s)淋巴 瘤、AIDS相關之淋巴瘤、惡性务 兒疫增殖疾病、多發性骨 髓癌及惡性血漿細胞贅瘤、淋p A , . · 白血癌、骨髓白血癌 '急 性或·1¾性淋巴白血癌、單核白血姑a - 衣白血癌、特定細胞類之 其他白血癌、—非特定細胞類之白 血癌、淋巴之其他及非特 定惡性-贅癌造血及相關組織 . 則如擴散之大細胞淋巴 瘸、T-細胞淋巴瘤或皮膚τ·細胞淋 、 *10- 本纸張尺度適用中國國家標準(CNS) A4規格(210X297公慶一) 1334350 A 7 -----:__B7 五、發明説明(· 7 ) 化學治療劑"一詞尤其指除雷帕黴素或其衍生物以外 之任何化學治療劑。其包含(但不限): '· 芳酶(81:〇11^1&56)抑 _制劑, 11 抗***、抗-男性激素(尤其***癌時)或促性 腺激素釋放因子促效劑, 111.括缚異構酶I抑制劑或拓樸異構酶π抑制劑, ιν.微管活化.劑、岑化劑、抗贅瘤抗代謝或氣氨鉑化合 物, V. 標的/降低、蛋白質或脂質激酶活性或蛋白質或脂質鱗 酸酶活性之化合物’近一步之抗血管形成之化合物或 誘發細胞分化過程之化合物, vi.緩激肤1受體或血管收縮素11结抗劑, VII.環氧酶抑制劑、雙膦酸鹽 '組織蛋白去乙醯酶抑制 劑、肝素酶(heparanase)抑制劑(避免肝素硫酸鹽降 解)’例-如PI-88 ’ 一種生物反應改質劑’較好為淋巴 素(lymphokine)或干擾素’例如干擾素丨、泛眼化抑 制,劑、或阻斷抗-細胞凋亡路徑之抑制劑, V1ii. Ras致癌基因等形之抑制劑,例如H_Ras ' K_Rasi N_
Ras或法呢基轉释酶抑制劑,例如匕_7斗4 戈 DK8G557 > ix.調聚酶(t£l〇merase)抑制劑,例如托羅美斯達汁 (telomestatin); x 蛋白酶抑制劍,基質金屬蛋白酶抑制劑,蛋氨酸胺基 肽酶抑制劑’例如苯胍麥(bengamide)或其衍生物,或 1334350 A7 B7 五、發明説明(·8 ) 蛋白質體抑制劑,例如PS-34丨。 本文中所用"芳酶抑制劑”係有關抑制***產生之化 合物,亦即使受質雄烯二酮及睪丸素分別轉化成雌素酮及 雌吞醇。該詞包含(但不限於)類固醇,尤其是阿它美山 (atamestane)、心美山(exemestane)及法美山(formestane) ’ 尤其是非類固醇’尤其胺基殼酷胺(aminoglutethimide)、羅 設醯胺(roglethimide) ' σ比淀榖 胺(pyridoglutethimide)、催 維山(trilostane)、睪内酉旨(testolactone)、酮康咏 (ketokonazole)、瓦羅吨(voroz〇ie)、法多。坐(fadr〇z〇ie)、納 托唑(anastrozole)及利托唑(ietroz〇ie)。心美山可以例如商 標A ROM AS⑴…銷售之形式投藥。法美山可以例如商標 LENTARONtn^售之形式投藥。法多唾可以例如商標 AFEMAtm銷售之形式投藥。納托唑可以例如商標 ARIMIDEXtm銷售之形式投藥。利托唑可以例如商標 FEMARA表FEMARtm—售之形式投藥。胺基榖醯胺可以 例如商標ORIMETENT、g售之形式投藥。包括芳酶抑制劑 化學治療劑之本發明组合物尤其可用於治療荷爾蒙受體陽 性腫瘤,例如***腫瘤。 本文中所用”抗***”係有關在***受體程度下拮 才几***作用弋化合物。該詞包含(恒不限於)托莫希吩 (tam〇Xlfen)、氟瓦斯蘭(fulvestrant)、拉羅希吩(rai〇xifene) 及拉羅希吩鹽酸鹽。托莫希吩可以例如商標概v魔χΤΜ 銷售之形-式投藥。拉羅希吩可以例如商標ev1staTM鎖售 之形式投藥。氟瓦斯蘭可以如US d 。. -12- 1334350 A7 B7 五、發明説明(’ 9 配,或可以例如商標FASLODEX1'1"^·#售之形式投藥。包括 抗***之化學治療劑之本發明組合物尤其可用於治療雌 激素受體陽性腫瘤,例如***腫瘤。 本文中所用•,抗雄激素•,一詞係關於任一種可抑制男性 荷爾蒙激素之生物作用之物質,且包含(但不限)可如u S 4,636,505中所揭示般調配之雙卡盧麥(bicalutamide) (CAS0DEXTM)。 本文中所用之”***釋放因子促效劑’’包含(但不 限)阿巴列'絲(abarelix)、哥斯林(gosere丨in)及哥斯林乙酸 鹽。哥斯林揭示於US 4,100,274中,且可以例如商標 Z0LADEXTM銷售之形式投藥。阿巴列絲可以如US 5,843,90 1號中揭示般調配。 本文中所用”拓樸異構酶I抑制劑"一詞包含(但不限)托 波肯(topotepan)、愛諾肯(irinotecan)、9-硝基喜樹驗及巨分 子喜樹鹼共鲆物PNU-166148 (W0 99/17804之化合物A1)。 愛諾肯可以例如商標CAMPTOSARtm銷售之形式投藥。托 波肯可以例如商標HYCAMTINtm銷售之形式投藥。 本文中所用"拓樸異構酶II抑制劑"包含(但不限於)蒽環 素如多索盧濱(doxorubicin)(包含脂質體調配物’例如 CAELYX™)、道諾盧濱(daunorubicin)、愛比盧濱 (epirubicin)、 愛多盧濱(idarubicin)及泥莫盧濱 (nemorubicinj、恿g昆米托山酉同(mitoxantrone)及羅索山_ (losoxantrpne·)及鬼臼脂素(podophillotoxines)愛托普塞 (etoposide)及用·泥普塞(teniposide)。愛托普塞可以例如商 -13- 本紙張尺度適用中因國家標準(CNS) A4規格(210 X 297公釐〉
1334350 A7
1334350 A7 ----;___ B7 五、發明説明(‘ h ) (inet:hotiexiUe) & 達催特(edat丨,exate)。卡配塔濱可以例如 商標\£[^00八旧銷售之形式投藥。葛麥塔濱可以例如商標 G£MZARTN^)ij售之形式投藥。 本文中所用"氣氨鉑化合物"一詞包含(但不限)碳氣氨 始、順氣氨舶及氧雜氣氨銷(〇xaliplatjn)。碳氣氨銷可以例 如商標CARBOPLATtm銷售之形式投藥。氧雜氯氨鉑可以 以例如商標ELOXATINtm之形式投藥。 至於本文中所用,_標的/降低蛋白質或脂質酶活性之化合 物或其他抗-血管形成之化合物"一詞包含(但不限)蛋白質 酪胺酸激酶及/或絲胺酸及/或蘇胺酸激酶抑制劑,或脂質 激酶抑制劑,例如標的、降低或抑制受體酪胺酸激酶 (EGFR、ErbB2、ErbB3、ErbB4 ’如均-或雜二聚物)之表皮 生長因子家族,受體酪胺酸激酶(VEGFR)之血管内皮生長 因子家族,血小板衍生之生長因子受體(PDGFR)、纖維組 織母細胞生長因子-受體(FGFR)、類胰島素生長因子受體1 (IGF-1R)、Trk受體酪胺酸激酶家族、Αχ丨受體酪胺酸激酶 家族、Ret受體酪胺酸激酶、Klt/SCFR受體酪胺酸激酶、c_ Ab丨族及其基因融合產物之成員(例如、蛋白質激 酶C(PKC)及絲胺酸/蘇胺酸激酶Raf族之成員、MEK、 SRC、JAK、FAK' PDK或Pl(3)激酶家族之成員,或ρι(3)_ 激酶-相關之激酶家族,及/或胞轉蛋白相關之激酶家族 (CDFC)之成員及對其活性具有另一機制之抗·血管形成化 合物,例如與蛋白質或脂質激酶抑制作用無關者。 標的、降低或抑制VEGFR活性之化合物尤其為可抑制 _ -15- 本紙張尺度適;?!中8 a家標準(CNS) A4規格(21GX 297公爱) -------- 1334350 A7 ____ .___B7 五、發0月説明(12 ) VEGF受體酪胺酸激!|每、抑制VEGF受體或結合至VEGF之 化合物、蛋白質或抗體,且尤其為基因工程之該等化合 物、蛋白質或單株抗體,尤其揭示於W 0 98/35958者,如 1-(4-氣苯胺基)-4-(4-吡啶基甲基)Si;畊或其醫藥可接受性 鹽,如琥珀酸鹽或揭示於WO 00/09495、WO 00/27820、 WO 00A59509、WO 98/11223、WO 00/278 19 及 EP 0 769 947 ; M· Prewett 等人於 Cancer Research 59 (1999) 5209-5218, F. Yuan等人於 Proc. Natl. Acad. Sci. USA,卷 93,第 14765-14770 頁(1996 年 12 月)、Z. Zhu 等人於 Cancer Res. 58, 1998, 3209-32 14 及 J. Mordenti 等人於 Toxicologic Pathology,卷 27, 第1期,第14-21頁(1999)所述者、揭示於WO 00/37502及 WO 94/10202 者;AngiostatinTM,M. S. O'Reilly 等人於 Cell 79,1994,3 15-328所述者;£ndostatinTM,M. S. O'Reilly等人 於 Cell 88,1997,277-285 所述者;蒽甲酸醯胺;ZD4 190 ; ZD6474 ; SU5416 ; SU6668 ;或抗-VEGF抗體或抗-VEGF受 體抗體如RhuMab。 抗體意指完整之單株抗體、多株抗體、由至少2個完整 抗體所形成之多特異性單株抗體、及抗體片段,只要其可 展現所需生物活性即可。 可標的、降低或抑制表皮生長因子受體家族活性之化合 物特別為可抑制EGF受體酪胺酸激酶家族如EGF受體、 ErbB2、ErbB3及ErbB4之成員或可結合至EGF或EGF相關配 位體之化-合物、蛋白質或抗體,且尤其是經基因工程之該 等化合物、蛋白質或單株抗體且尤其揭示於 L____ -16- ^纸張尺度通用中國国家標準(CNS) A4規格G10x297公發y 1334350 A7 B7 五、發明説明(13 97/02266 ’如實例39之化合物或於EP 0 564 409、WO 99/03854、EP 0 520 722 ' EP 0 566 226、EP 0 787 722、EP 0 837 063、US 5,747,498、WO 98/10767、WO 97/30034、 WO 97/49688、WO 97/3 8983 及尤其 WO 96/30347所述者(如 稱為CP 358774之化合物)、w〇 96/33980(如化合物ZD 1839) 及WO 95/03283(如化合物ZM105 180);如托土乳馬 (trastuzumab) (HerpetinR)、希土馬(cetuximab)、愛利沙 (Iressa)、OSI-774、CI-1033、EKB-569、GW-2016、E1.1、 E2.4、E2.5、E6.2、E6.4、E2.ll ' E6.3 或 E7.6.3 者。 可標的、降低或抑制PDGFR活性之化合物尤其為可抑制 PDGF受體之化合物’如N-苯基-2-嘧啶-胺衍生物如衣馬替 尼(imatinib)。 可標的、降低或抑制e-Abl家族成員及其基因融合產物 活性之化合物如N-苯基-2-嘧啶-胺衍生物如衣馬替尼 (imatinib) ; PD180970 ; AG957 ;或 NSC 680410。 _ 可標的、降低或抑制蛋白質激酶C、Raf、MEK、SRC、 JAK、FAK及PDK家族成員或ρι(3)激酶或p丨(3)激酶相關家 族成員及/或胞轉細胞相關之激酶家族(CDK)之活性之化合 物尤其為揭示於EP 〇 296 1 10之該等十字環孢素 (staurosporine)衍生物’如咪多塔寧(midostaurin);進一步 化合物貫例包含UCN-01、沙吩果(safin.g〇i)、BAY 43_ 9006、伯牙斯達汀(Bryostatin) 1、伯利辛(perifosjne);衣 莫辛(11111(^〇4116);11〇 3 18220及11〇 320432;〇〇 6976;1513 3521 ;或 LY333531/LY379196 。 -17- 本纸張尺度適用中國國家橾準(CNS) A4規格(210 X 297公釐) 1334350 A7 B7 五 發明説明(’ 14 進一步抗-血管形成化合物為例如塞利多胺(thalidomide) (THAL0MID)及 TNP-470。 可標的、降低或抑制蛋白質或脂質磷酸酶活性之化合物 為例如磷酸酶1、磷酸酶2A、PTEN或CDC25之化合物,如 歐達酸(okadaic acid)或其衍生物。 可誘發細胞分化過程之化合物為例如視黃酸、α 7 -或5 -生百盼或α-、7-或(5-生育三晞酿·。 環氧酶抑制劑一詞包含(但不限於)希來可希(celecoxib) (CelebrexR)、羅酚可希(rofecoxib) (VioxxR)、愛托利可希 (etoricoxib)、凡得可希(valdecoxib)或5-烷基-2-芳胺基苯基 乙酸如5-曱基-2-(2,-氣-6,-氟苯胺基)苯基乙酸。 本文所用之"組織蛋白去乙醯酶抑制劑"包含(但不限於) MS-27- 275、SAHA、比羅麥(pyroxamide)、FR-901228 或瓦 普酸(valproic acid)。 本文所用雙騰酸鹽"包含.(但不限於)愛催多酸(etridonic acid)、羅多酸(clodronic acid)、替盧多酸(tiludronic acid)、 潘米多酸〔pamidroni.c acid)、愛蘭多酸(alendronic acid)、愛 班多酸(ibandronic acid)、瑞絲多酸(risedronic acid)及吨多 酸(zoledronic acid)。"愛催多酸,,可以商品名DIDRONELtm 銷售之形式投藥。”羅多酸"可以商品名bonefostm銷售 之形式投藥。"替盧多酸"可以商品名5匕已匕10]銷售之形 式投藥。"潘米多酸"可以商品名ARE DIATM銷售形式投 藥。"愛蘭I-酸”可以商品名?0$八1\4八乂1^銷售形式投藥》 •’愛班多酸’•可以商品名BOND RAN八丁…銷售形式投藥。 -18- 本紙張尺度適用中闺國家標準(CNS) A4规格(210 X 297公釐) 1334350 A7 __‘_ B7 五、發明説明(’ 15 ) "~'~~' 〜-- "瑞絲多酸"可以商品名ACTONEI ΓΜ4>ί佳犯l t l鈉丟形式投藥。,,唑多 酸’’可以商品名20"£丁八"^銷售形式投藥。 本文所用之"基質金屬蛋白酶抑制劑”包含(但不限於)膠 原擬肽及非擬肽抑制劑 '四環素衍生物如㈣酸醋擬肽抑 制劑貝替莫斯特(batlmastat)及其σ服生物可利用類似物馬 利莫斯特(marimastat)、平諾莫斯特({)_〇11^如)、81^_ 27925i、ΒΑΥ 12-9566、ΤΑΑ2ΐβΑΑ:ί996。, 在提供引述專利申請案或科學公報之例中,與該化合物— 有關之主體因此併入本發明供參考。類似地包括其醫藥可 接受性鹽、對應消旋物、非對映異構物、對映異構物、互 變_體及存在之上述化合物之對應結晶改質物,溶劑化物、 水f物及多一晶型,其揭示於本文。於本發明組合物中作為 活性成分之化合物可分別如所引證文獻所述般製備及投 暮亦在本發明範圍内者為兩種以上之上述個別活性成分 之組合,亦即本發明範圍内之醫藥組合物可包含三種活性_ 成分或以上。又第一藥劑及輔藥劑兩者並非相同成分。 式1化合物於治療上述實心腫瘤之利用性可於動物測試 方法及臨床(例如依據下述方法)試驗中證明。 A.體外 A. 1與其他藥劑組合之抗増殖活性 細胞株如化合物A抗性之A549細胞株(於低nM範圍之IC50) 相對比較性化合物A抗性KB-3丨及HCT丨丨6細胞株(μ Μ範圍: 内之丨Cso)添加至9$-洞盤(於1〇〇微升培養基之丨,500細胞/洞) 中及培育24小、時。隨後’於個別試管中製作各化合物之兩 _______ -19- 本紙張困.國家標準(CNS>八4@(21〇 X 297公釐)----- A7
-,a人此Λ & 環,丨j組合之有用抗增殖活性。例如. 以化合物A-與順氯氨鉑' 砧 .‘ 人括利塔索、葛麥塔濱及多索盧濱 μ合獲得下列CI值一
細胞株 ΚΒ-31 Α549 HCT1 16 順氣氨鉑 0.74 0.47 0.47 葛麥塔濱 0.79 0.76 0.9 多索盧濱 0.7 0.64 0.52 再者,此分析中,化合物Α當與葛麥塔濱組合使用時 強效地喪失Α549細胞存活性及細胞死亡。 Α.2抗血管形成活性 訂 倍連續稀釋(式I化合物 ICso之8倍開始),可單獨知〈化學治療劑)(自各化今物 中。細胞接著再培育3天2成對組令,及稀釋液添加至洞 結合之染料量(與^ “在第4天進行甲基I著色及測定 用caicusyn·式測定ICs ,〈存活細胞數之比例)。隨後使 折神非Μ从Μ·, Κ )〇 ’其可提供相互作用指標’亦即 所明非排他性組合指數( 1 ^ m · n OC η 〇 ^ ) ’其中CI〜1 =幾近加成之相互 作用,0.8)-0.9=略相乘. L ,<()·85 =相乘。此分析中,式I化- 合物顯π與其他化學治療
裝
線 雷帕黴素或其衍生物如化合物八抗人類臍靜脈表皮細胞 (HlJVECs)之抗增殖體外分析中證明對vegF-及bFGF-及 FBS-刺激之增殖作用之IC5〇值分別為12〇± 22 ρΜ及841 土 396及〉10000 ρΜ。此外’化合物Α對bFGF-刺激之正常人 — *·*· 類皮膚纖雖母細胞(NHDF)增殖在相同濃度範圍内並無明 顯效果。該等結果顯示化合物A可抑制HUVECs增殖作 -20- 本纸張尺度通用中國國家標準(CMS) A4規格(210 X 297公釐) 1334350 A7 B7 五、發明説明(22 ) 〆 主要目的:鑑定該式丨化合物如化合物A之最佳劑量,每 週腹膜内投與一次’假設此需為與該化合物之mTOR 及血管中延長抑制作用至少等於於體内臨床前量之抗 腫瘤效果之作用有關之最小劑量。 次要目的:當僅對癌症病患投藥時評估該化合物之安全性 及評估腫瘤代謝活性變化。 設計:連續4組患有末期惡性實心腫瘤且對標準療法具難 一 治癒性或抗性之病患每7天接受不同劑量之式I化合物 如化合物A(組1接受乏毫克;組2接受1 〇毫克;组3接受 20毫克)共4週。第4週,藉末梢淋巴細胞中p70s6激酶 抑制作用反應建立藥效性輪廓及mTOR抑制作用輪 廓。進行比較性1 8-氟去氧葡萄糖(FDG)陽電子放射局 部X光照射(FDG-PET)攝影(第1次投藥前及第3次投藥' 後)以探究腫瘤遷移變化。 病患主要選擇標準:患有末期(III-V)實心腫瘤、對標準療 -法具抗藥性或難治癒性之成人。至少一個腫瘤病害需 可測量(一方向> 20毫米)。 主要評估變數:安全性(不利事件)、標準血漿生化性及血 液學、欲測試化合物之血液量、淋巴細胞p70-s6激酶 活性、FDG-PET之腫瘤葡萄糖攝取變化。 部分2 : _ 主要標的:.探究式I化合物如化合物A對末期實心腫瘤病 :. 患-以-最適劑量(如部分1中藉腫瘤反應所示般慰定)每 週投藥一次之效果。 _ -26- 本纸張尺度適用中國圔家搮準(CNS) A4規格(210 x 297公釐) 1334350 A7
訂
裝
1334350
1)式丨化合物如化合物A,及 b)作為輔藥劑之一或多種上毕段落(i〇、(Hi)或(iv)所述化 合物’如碳氯氨鉑、順氣氨鉑、帕利塔索、多塞塔索、葛 麥塔濱或多索盧濱。 r 式〖化合物如化合物A與碳氣氨鉑、順氣氨鉑、帕利塔 索、多塞塔索、葛麥塔濱或多索盧濱之相乘組合較佳。 又較佳醫藥組合物為例如包括下列之組合: a) 雷帕徽素或其衍生物如CCI_779、ABT578或化合物A,及 b) 作為輔藥劑之一或多種上述段落⑴及⑺至⑴之化合 w *- * 物’較好為上述段落(v)之一或多種化合物。較佳為例如 雷帕黴素或其衍生物如CCi_779、ABT578或化合物a與上 迷 < 可標的、降低或抑制VEGFR、EGFR家族、PDGFR、c- ΑβΙ永族成員或蛋白質激酶C之化合物之相乘組合物。 本發明一特定具體例有關使用本發明組合物用以預防、 延遲發展或治療或製備可預防、延遲發展或治療乳癌之醫 藥 < 用途。較好此具體例中,此組合包括作為輔藥劑b)之 荄酶抑制劑如芳酶抑制劑利托唑、抗雌攀素如托莫希吩' 拓樸異構酶抑制劑如多索盧濱、或微,管活性劑如帕利塔 索。 本發明另一具體例係有關本發明組合物用以預防、延遲 發展或治療或製備可預防、延遲發展或治療肺癌之醫藥之 用途。較好此具體例中,此組合包括作為輔藥劑b)之氣氨 %化合物如破氣氨鉑或微管活性劑如帕利塔索。 本發明另一具體例係有關本發明組合物用以預防、延遲
裝 訂
终 -29-
1334350 A7 ------ B7 五、發明説明(26 ) 發展或治療或製備可預防、延遲發展或治療胰癌之醫藥之 用途。較好此具體例中,此組合包括作為輔藥劑b)之抗贊 瘤抗代谢物如葛麥塔濱。 本發明另一具體例係有關本發明組合物用以預防、延遲 發展或治療或製備可預防、延遲發展或治療神經母細胞癌 癌(醫藥之用途。較好此具體例中,此組合包括作為輔藥 劑b)之烷化劑如BCNU。 本發明又一具體例係有關使用上述雷帕黴素或其衍生物 與化子/〇療劑以治療淋巴癌之用途。該組合物又可包括作 為輔藥劑b)之馬利蘭(busulfan)、阿糖胞荅(cytarabine)、6_ 奴代鳥嘌呤、氟達拉濱(fludarabine)、羥基尿素、甲基苄 丼(procarbazine)、博來黴素(bie〇mycin)或美托催特。拓樸 異構酶II抑制劑如道諾盧濱或尤其可標的、降低或抑制 PDGFR或c_Abl家族成員及其基因融合產物之化合物如衣 馬替尼為較佳之輔藥劑(b)。 电本又中”共同投藥”或"組合投藥"等意指包含對單一病 患之選擇治療劑之投藥且欲包含其中藥劑未必藉相同投藥 路徑或相同時間投藥。 本發明-目的係提供—種醫藥组合物,包括組合有效治 療抗惡性疾病之量之包括本發明之組合。此組合物 中,第一藥劑a)及輔藥劑b)可—起投藥,可依序投藥或於 -組合單位劑型或兩個分開之單位劑型投藥。單亦 可為固定组合。 第一藥劑a)及輔藥劑b)分開投藥及以固定組合投藥之醫 -30- 本紙張尺度㈣巾S S家揉準(cf S) A4規格(210X297公釐) 1334350 27 五、發明説明( 藥組合物’亦即本發明之~^丨二. 單一藥用组人榀-〈包括玍少兩種組合夥伴a)及b)之 早头用組合物可藉本技蓺P ^ 士斗.Μ 口服或古胳 π已知万式製備且為適於經腸如 服4直%、及非經腸道 t哺礼颏(/政血動物包含人類)投 =包=療有效量之單獨之上述至少一種醫藥活性組 :1於”一或多種醫藥可接受性載體或稀釋劑組合, 尤其適於經腸或非經腸道施用者。 適宜醫藥組合物含有例如約01%至約99,。,較好約1% =60%活性成分。經腸或非經腸道投藥之組 或安咬。者如糖歧、鍵劑、膠囊或栓劑 揲其他指示,其藉本技藝悉知方式製備,作“ 楮習:混纟、造粒、包糖衣、溶解或凍乾製程。需了解含 於各劑型中個別劑量所含之組合夥伴單位含量本二 成有效量,因可藉投與數個劑型單位達到必要有效量。 =,本發明、組合之各組合夥伴之治療有效量=時或 依序或以任何次序擐藥’且成分可分別或以固定乜人浐 樂。例%,本發明之延遲發展或治療增殖惡性疾病之= I,括同時或依子⑴以游離或醫藥可接受性鹽態投與第二 樂劑a)及(π)以游離或醫藥可接受性鹽態投與輔藥劑I)弟以 结合治療有效量投藥,較好為相乘效果量,如對應於本' 量之日劑量或間歇量。本發明组合之各组合夥伴^ 1工又 期間不同時間分別投藥或同時以分開或單—組入释λ =療 再者’投藥-詞亦包括使用組合夥伴之前藥,:=内 轉化成組合夥伴。本發明因此需了解包含所有同時或交替 治療之攝取且據此可了解,,投藥”一詞"。 -31- 本纸張尺度適用中國國家標準(CNS) Α4规格(210Χ 297公爱) 1334350
本發明‘組合中所用之各組合夥伴t效劑量τ隨特定化合 物或所用醫藥組合物藥模式、欲治療病況、欲治療病 況嚴重性等而異。因此,本發明组合物之劑量攝取係依據 各種因素選擇,包含投藥路徑疾病患之腎及肝功能。本技 藝之醫師 '臨床師或默醫可決定且處方用以預防、治癒或 舒緩病況發展所需之該有效量之單—活性成分。達到產生 效果而無毒性之範圍内之活性成分濃度之最適精確度需要 依據標地位置之活性成分利用性之動態學為主之攝取。 s然,第一藥劑a)<日劑量例如隨所選用之化合物 '欲 治療特定病況及所需效果而異。但通常,在單一劑量或數 次劑量之約0.丨至25毫克等級之日劑量範圍投與雷帕黴素 或其衍生物可達滿意之結果。雷帕黴素或其衍生物如式j 化合物可藉任何習知途徑投藥,尤其以錠劑、膠囊、飲用. 溶液經腸如口服投藥,或如可注射溶液或懸浮液非經腸道 投藥。口服投藥之適宜單位劑型包括约〇,〇5至1〇毫克活性 成分如化合物A與一或多種其醫藥可接受性稀釋劑或載體 組合。 法多吐可以約0.5至約10毫克/天,較好約i至約2 5毫克/ 天之變化劑量範圍對人類口服投藥。心美山可以約5至約 200毫克/天’較好約1〇至約25毫克/天之變化劑量範圍對人 類口服投藥或約50至500毫克/天,較好100至約25〇毫克/天 非經腸道投藥。若藥物須以分開醫藥組合物投藥,其可以 如082..,127,700所揭示劑型投藥。法美山可以約1〇〇至5〇〇 毫克/天’較好約250至約300毫克/天之變化劑量〜範圍對人 -32- ____ ___ 本紙蒗尺度通用_國國家標準(CMS) A4規格(21〇x 297公爱) A7 B7
經腸道投藥。納托唑可以約〇 25至2〇毫克/ 1334350 五、發明説明 類非經腸道投藥
投藥。 克/天,較好約 服投藥。胺基 量範圍對人顧
量範園對人類 投藥。
八〜乂儿劑量範圍對人類 25 土 〇.〇5笔克/公斤體重*週之變 文S若利濱可以约10至50毫克/m2 天之變化劑量範圍對人類投藥。 一愛托普塞磷酸鹽可以約25至Π5毫克/m2天如56 8或1丨3 6 毫克/m2天之劑量變化範圍對人類投藥。 坍泥普塞可以約每2週約75至150毫克之劑量變化範圍對 人類投藥。多索盧濱可以約10至1〇〇毫克/m2天如25或5〇毫 克/m天之刎f變化範圍對人類投藥。愛比盧濱可以約^ 〇 至200毫克/m2天之劑量變化範圍對人類投藥。愛多盧濱可 以約0.5至50鼋克/m2天之劑量變化範圍對人類投藥。米托 山酮可以約2.5至25毫克/m2天之劑量變化範圍對人類投 藥。 帕利塔索可以约5〇至3〇〇毫克/m2天之劑量變化範圍對人 類投藥。多塞塔索可以約25至1〇〇毫克/m2天之劑量變化範 圍對人類投藥。 環罐St f孓以约50至1500毫克/m2天之劑量變化範圍對 人類投藥。美分蘭可以約0 5至丨〇毫克/m2天之劑量變化範 本紙浪尺度適用中固國家標準(CNS)A4規格(210X297公釐) 1334350 A7 __ B7 五、發明説明(30 )~" ' 圍對人類投藥。 5-氟尿嘧啶可以約5〇至丨〇〇〇毫克/m2天如5〇〇毫克/m2天之 劑量變化範園對人類投藥。卡配塔濱可以約丨〇至丨〇〇〇毫克 /m2天之2劑量變化範圍對人類投藥。葛麥塔濱可以約丨〇〇〇 毫克/m2/週之劑量變化範圍對人類投藥。 美托催特可以約5至500毫克/m2天之劑量變化範圍對人 類投藥。 托波肯可自約1至5毫克/m2天之劑量變化範圍對人類投 藥。愛諾3可自約5 0至3 5 0毫克/m2天之劑量變化範圍對人 類投藥。 碳氣氨鉑可以約每4週約200至400毫克/m2之劑量範圍對 人類投藥。順氣氨鉑可以約每3週約25至75毫克/m2之劑量 範圍對人類投藥。氧氯氨鉑可以每2週約5〇至85毫克/m2之-劑量變化範圍對人類投藥。 衣馬替尼可自約2.5至850毫克/天,更好5至600毫克/天 且最好20至3 00毫克/天之劑量範圍對人類投藥。 3:蘭多酸可自約5至1 〇毫克/天之劑量變化範圍對人類投 藥。羅多酸可自例如約750至1500毫克/天之劑量變化範圍 對人類投藥。愛催多酸可自約200至400毫克/天之劑量變 化範圍對人類投藥。愛班多酸可自每3至4週約1至4毫克對 人類投藥。瑞絲多酸可以約20至30毫克/天之變化劑量範 圍對人類投藥。潘米多酸可以每3至4週自約15至90毫克之 變化劑量輯圍·對人類投藥。替盧多酸可自約200至400毫克 /天之劑量變化範圍對人類投藥。 -34- 本纸張尺度適用中國國家標率(CNS) A4規格(210X297公釐) 1334350 A7
忙上孔馬(Trastu 人類投藥。 &卡盧麥(Bicalutamide)可以約25至50毫克/m2 範圍對人類投藥。 \剞| 1 (4-亂苯胺基)_4_(4-σ比咬基甲基)g太b井或其鹽如球 可以劑量範圍約50至1500,更好約1〇〇至75〇且最好鹽 至5〇〇毫克/天對人類投藥。 岣 雷帕黴素或其衍生物在本發明用途所需劑量下具有、 耐藥性。例如化合物A之NTEL於4週毒性研究中於大 0-5毫克/公斤/天及於猴子為15毫克/公斤/天。 -35-
Claims (1)
1334350 第091102797號專利申請案 ^ 中文申請專利範圍替換本("年3月) 品
1. 一種40-0-(2-羥基乙基)·雷帕黴素之用途,其係用以製備 用於治療實心腫瘤之醫藥組合物 該實心腫瘤係選自腦及其他中樞神經系統腫瘤、頭及/或 頸之癌症、循環系統腫瘤、***系統之腫瘤、腸胃道1 瘤、包含肝臟及内部膽汁導管、膽囊、其他及未二=部 分之膽道、口腔、再生系統之腫瘤、呼吸道腫瘤之鼻腔 及中耳,副竇、喉頭、氣管 '支氣管、骨骼系統腫瘤、 皮膚腫瘤、淋巴結之第二種之惡性腫瘤,及呼吸及消化 系統之第二種惡性腫瘤。 2. 如申請專利範圍第1項之40·〇_(2_羥基乙基)_雷帕黴素之 用途,係用於製造用以治療實心腫瘤侵入或與此腫瘤生 長有關之病徵之醫樂組合物。 3. —種40-0-(2-羥基乙基)-雷帕黴素之用途,其係用以製備 用於抑制或控制血管形成失調之醫藥組合物。 4· 一種40-0-(2-羥基乙基)-雷帕黴素之用途’其係用以製備 用於治療與血管形成失調相關之疾病之醫藥組合物。 5. 如申請專利範圍第丨或2項之用途,其係治療腦及其他中 枢神經系統腫瘤、結腸、結直腸或再生系統之腫瘤。 6. 如申請專利範圍第i、3或4項中任一項之用途,其中醫藥 組合物係為間歇性投藥。 7. 如申請專利範圍第6項之用途,其中該醫藥組合物係為 與照射治療併用。 8. —種用於治療實心腫瘤或抑制或控制血管形成失調、或 治療與血管形成失調相關之疾病之醫藥組合,其包括a) 76701-990323.doc 本纸張尺度適用中國國家標準(CNS)A4規格(210x297公爱) 1334350 A8 B8 C8 D8 六、申請專利範圍 第一劑,其為40-0-(2-羥基乙基)-雷帕黴素; 及b ) —種化學治療劑之輔藥劑,其係選自: i. 芳酶(aromatase)抑制劑,其係選自阿它美山 (atamestane)、心美山(exemestane)、法美山 (formestane),胺基榖醯胺(aminoglutethimide)、羅 榖醯胺 (roglethimide) 、 ?比咬榖酿胺 (pyridoglutethimide)、催羅山(trilostane)、睪内醋 (testolactone)、_ 康 °坐(ketokonazole)、瓦羅0坐 (vorozole)、法多0坐(fadrozole)、納托0坐(anastrozole) 及利托 °坐(letrozole); ϋ. 拓樸異構酶II抑制劑,其係選自於蒽環素、蔥醌米 托山酮(mitoxantrone)及羅索山酮(losoxantrone); iii. 微管活化劑、烷化劑、抗贅瘤抗代謝或氣氨鉑化合 物; iv. 標的/降低蛋白質或脂質激酶活性或蛋白質或脂質 填酸酶活性之化合物,近一步之抗-血管形成之化 合物或誘發細胞分化過程之化合物; v. 緩激肽1受體或血管收縮素II拮抗劑; vi. 環氧酶抑制劑、雙膦酸鹽、組織蛋白去乙醯酶抑制 劑、肝素酶(heparanase)抑制劑、生物反應改質劑、 泛醌化抑制劑、或阻斷抗-細胞凋亡路徑之抑制 劑; vii. Ras致癌基因等形之抑制劑; viii. 調聚酶抑制劑;及 76701-990323.doc -2- 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公釐) 1334350 A8 B8 C8 D8
ix蛋白酶抑制劑,基質金屬蛋白酶抑制劑,蛋氨酸胺 基肽酶抑制劑,或蛋白質體抑制劑。 9. 一種用於治療實心腫瘤或抑制或控制血管形成失調、或 治療與血管形成失調相關之疾病之醫藥組合其包括a) 第一劑,其為40-0-(2-羥基乙基)-雷帕黴素; 及b) —種化學治療劑之輔藥劑,其係選自帕利塔索 (paclitaxel)、葛麥塔濱(gemcitabine)、順氣氨舶 (cisplatinum)、多索盧濱(doxorubicin)、5-氟尿咬(5- fluorouracil)、抗代謝物、生物反應改性劑、表塞_ (epothilones)或其衍生物。 10_如申請專利範圍第8項之醫藥組合,其中輔藥劑係選自 阿它美山(atamestane)、心美山(exemestane) '法美山 (formestane) ’ 胺基穀醯胺(aminoglutethimide)、羅榖醯 胺(roglethimide)、p比咬榖醯胺(pyridoglutethimide)、催羅 山(trilostane) '睪内醋(testolactone)、酮康 〇坐 (ketokonazole)、瓦羅吐(vorozole)、法多吐(fadrozole)、 納托0坐(anastrozole)及利托 '•坐(letrozole)之芳酶(aromatase) 抑制劑。 11. 如申請專利範圍第1〇項之醫藥組合,其中芳酶(aromatase) 抑制劑為利托嗤(letrozole)。 12. —種用於治療實心腫瘤或抑制或控制血管形成失調、或 治療與血管形成失調相關之疾病之醫藥組合,其包括a) 第一劑,其為40-0-(2-羥基乙基)-雷帕黴素; 及b) —種化學治療劑之輔藥劑,其係選自於 -3- 76701-990323.doc 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公釐) 1334350 六、申請專利範圍 VEGF受體酪胺酸激酶抑制劑; EGF,ErbB2,ErbB3 或 ErbBq體路胺 劑及PDGF受體抑制劑。 轉抑制 η.如申請專利範圍第12項之醫藥組合,其中b)辅藥劑係 RhuMab,托 土乳馬(trastuzumab)、愛利 OSI-774 或衣馬替(imatinib) β Γ6883) ' 14. 如申請專利範圍第8、9、1〇或12項中任一項之— 合,其中a)第一劑’及b)輔藥劑係為同時或連:::組 15. 如申請專利範圍第8、9、1〇或12項中任—項之 合,其中a )第一劑為間歇性施用。 樂’且 16. 如申請專利範圍第14項之醫藥組合,其係與照射治療併 用。 17. 如申請專利範圍第15項之醫藥组合,其係與照射治療併 用。 ’、 18.—種如申請專利範圍第8、9、1 〇或丨2項中任—項之醫 藥組合之用途,其係用於製備用於治療實心腫瘤,其係 選自腦及其他中樞神經系統腫瘤、頭及/或頸之癌症、'乳 房腫瘤、循環系統腫瘤、***系統之踵瘤、腸胃道腫 瘤、包含肝臟及内部膽汁導管、膽囊、其他及未特定部 分之膽道、胰、其他及消化性器官之腫瘤、口腔、再生 系統之腫瘤、呼吸道腫瘤、骨骼系統腫瘤、皮膚腫瘤、 及包含其他組織之腫瘤,包含末梢神經及自主神經系 統、結締及軟骨組織、後腹腔及腹腔、眼睛及附件、甲 狀腺、腎上腺及其他内分泌腺及相關之結構 '淋巴結之 76701-990323.doc 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公楚) 1334350 A8 B8 C8 D8 六、申請專利範圍 第二種及未特定之惡性腫瘤及呼吸及消化系統之第二種 惡性腫瘤、其他部位之第二種惡性腫瘤或抑制或控制血 管形成失調或治療與血管形成失調相關之疾病之藥物。 76701-990323.doc -5- 本紙張尺度適用中國國家標準(CNS)A4規格(210x297公釐)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0104072A GB0104072D0 (en) | 2001-02-19 | 2001-02-19 | Organic compounds |
GB0124957A GB0124957D0 (en) | 2001-10-17 | 2001-10-17 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI334350B true TWI334350B (en) | 2010-12-11 |
Family
ID=26245731
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095103554A TW200626151A (en) | 2001-02-19 | 2002-02-19 | Cancer treatment |
TW091102797A TWI334350B (en) | 2001-02-19 | 2002-02-19 | Cancer treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095103554A TW200626151A (en) | 2001-02-19 | 2002-02-19 | Cancer treatment |
Country Status (27)
Country | Link |
---|---|
US (10) | US8410131B2 (zh) |
EP (11) | EP2783686B1 (zh) |
JP (14) | JP2004525899A (zh) |
KR (3) | KR20070102762A (zh) |
CN (5) | CN104274442A (zh) |
AU (1) | AU2002250968C1 (zh) |
BR (1) | BR0207378A (zh) |
CA (3) | CA2438504C (zh) |
CY (11) | CY1116616T1 (zh) |
CZ (5) | CZ200591A3 (zh) |
DK (6) | DK3143995T3 (zh) |
ES (8) | ES2543383T3 (zh) |
HK (7) | HK1146245A1 (zh) |
HU (1) | HUP0303271A3 (zh) |
IL (13) | IL157425A0 (zh) |
LT (9) | LT2762140T (zh) |
LU (3) | LU92880I2 (zh) |
MX (3) | MX368013B (zh) |
NO (14) | NO333105B1 (zh) |
NZ (1) | NZ527692A (zh) |
PL (5) | PL414997A1 (zh) |
PT (7) | PT2269604T (zh) |
RU (8) | RU2322981C2 (zh) |
SI (6) | SI3143995T1 (zh) |
SK (5) | SK288546B6 (zh) |
TW (2) | TW200626151A (zh) |
WO (1) | WO2002066019A2 (zh) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
PL414997A1 (pl) | 2001-02-19 | 2016-02-29 | Novartis Ag | Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki |
IL158800A0 (en) * | 2001-06-01 | 2004-05-12 | Wyeth Corp | Antineoplastic combinations |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
BR0313048A (pt) * | 2002-07-30 | 2005-06-14 | Zentaris Gmbh | Uso de alquilfosfocolinas em combinação com medicamentos antitumorais |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
CN100553634C (zh) * | 2002-10-11 | 2009-10-28 | 达纳-法伯癌症研究公司 | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
KR20120084333A (ko) * | 2004-02-23 | 2012-07-27 | 노파르티스 포르슝스티프퉁 쯔바이크니덜라쑹 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 | Mtor 억제제와 세포독성제의 복합 치료에 대한 바이오마커로서의 p53 야생형 |
GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
AU2005225192B2 (en) * | 2004-03-23 | 2008-10-09 | Astrazeneca Ab | Combination therapy |
BRPI0608152A2 (pt) | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
CN101137748B (zh) * | 2005-03-07 | 2011-12-14 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
JP2009501765A (ja) * | 2005-07-20 | 2009-01-22 | ノバルティス アクチエンゲゼルシャフト | ピリミジルアミノベンズアミドとmTORキナーゼ阻害剤の組み合わせ |
CN101360495B (zh) | 2005-11-14 | 2012-03-14 | 阿里亚德医药股份有限公司 | 对癌症病人给药mTOR抑制剂 |
ES2481671T3 (es) * | 2005-11-21 | 2014-07-31 | Novartis Ag | Inhibidores de mTOR en el tratamiento de tumores endocrinos |
HUE037890T2 (hu) | 2006-02-02 | 2018-09-28 | Novartis Ag | Sclerosis tuberosa kezelése |
GB0602123D0 (en) * | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
CA2645488C (en) | 2006-03-23 | 2014-09-02 | Macusight, Inc. | Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions |
RU2447891C2 (ru) * | 2006-04-05 | 2012-04-20 | Новартис Аг | Комбинации терапевтических средств, предназначенные для лечения рака |
EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER |
US9820888B2 (en) | 2006-09-26 | 2017-11-21 | Smith & Nephew, Inc. | Wound dressing |
PL2131821T3 (pl) * | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
CN101292980B (zh) * | 2007-04-28 | 2010-11-10 | 上海交通大学医学院附属仁济医院 | 一种含有雷帕霉素的用于治疗大肠癌的药物组合物 |
EP2190409B9 (en) * | 2007-08-16 | 2019-03-06 | Biocompatibles UK Limited | Delivery of drug combinations |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
US20120040896A1 (en) * | 2008-04-11 | 2012-02-16 | The Regents Of The University Of Colorado | Compositions, methods and uses for modulation of brca 1 |
EP2318529B1 (en) * | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
EA036314B1 (ru) | 2010-08-20 | 2020-10-26 | Новартис Аг | Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака |
EA036739B1 (ru) | 2011-12-05 | 2020-12-15 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3) |
DK3354293T3 (da) | 2012-05-23 | 2020-02-17 | Smith & Nephew | Apparater til sårbehandling ved negativt tryk |
US10667955B2 (en) | 2012-08-01 | 2020-06-02 | Smith & Nephew Plc | Wound dressing and method of treatment |
CN104661626B (zh) | 2012-08-01 | 2018-04-06 | 史密夫及内修公开有限公司 | 伤口敷料 |
US10493184B2 (en) | 2013-03-15 | 2019-12-03 | Smith & Nephew Plc | Wound dressing and method of treatment |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
PT3277842T (pt) * | 2015-08-17 | 2019-09-05 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
MX2018011101A (es) * | 2016-03-15 | 2018-11-22 | Tyme Inc | Composiciones farmaceuticas para el tratamiento del cancer. |
WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
ES2914123T3 (es) | 2017-01-09 | 2022-06-07 | Shuttle Pharmaceuticals Inc | Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
JP7217241B2 (ja) | 2017-06-30 | 2023-02-02 | ティージェイ スミス アンド ネフュー リミテッド | 陰圧創傷治療装置 |
WO2019089556A1 (en) * | 2017-10-31 | 2019-05-09 | Steve Gorlin | Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof |
WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CA3098698A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
PE20212112A1 (es) | 2018-05-01 | 2021-11-04 | Revolution Medicines Inc | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor |
CN108825638A (zh) * | 2018-08-01 | 2018-11-16 | 安徽送变电工程有限公司 | 一种应用于螺纹工件的防盗装置 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
US11534420B2 (en) | 2019-05-14 | 2022-12-27 | Tyme, Inc. | Compositions and methods for treating cancer |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
KR20230053539A (ko) | 2021-10-14 | 2023-04-21 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US876165A (en) | 1904-05-11 | 1908-01-07 | George K Woodworth | Wireless telegraph transmitting system. |
GB104072A (en) | 1916-04-14 | 1917-02-22 | William Henry Nosworthy | Apparatus for Lighting Fires or Heating or other purposes. |
GB124957A (en) | 1918-06-04 | 1919-04-10 | Frederick William Miller | Improvement in Glass Moulding. |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
JP3140228B2 (ja) * | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (zh) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
WO1994009019A1 (en) | 1992-10-14 | 1994-04-28 | Unichema Chemie B.V. | Process for the preparation of alkylglycosides |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DE4301781C2 (de) | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
GB9325400D0 (en) | 1993-12-11 | 1994-02-16 | Sarll David P G | Temperature recorder |
NZ277498A (en) | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
AU2356195A (en) * | 1994-04-14 | 1995-11-10 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
PT833828E (pt) * | 1995-06-09 | 2003-02-28 | Novartis Ag | Derivados de rapamicina |
MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
US5567831A (en) * | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
AU3257297A (en) * | 1996-06-11 | 1998-01-07 | Novartis Ag | Combination of a somatostatin analogue and a rapamycin |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
CN1235608A (zh) | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
GB9619631D0 (en) * | 1996-09-20 | 1996-11-06 | British Biotech Pharm | Combination therapy |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6152347A (en) | 1998-01-30 | 2000-11-28 | Acco Brands, Inc. | Vertical Stapler |
WO1999049863A1 (fr) | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
US8029561B1 (en) * | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
JP3732525B2 (ja) * | 1998-04-27 | 2006-01-05 | アステラス製薬株式会社 | 医薬組成物 |
EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
DE69926536T3 (de) | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
EP1074265A1 (en) | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
WO2001012633A1 (en) | 1999-08-18 | 2001-02-22 | American Home Products Corporation | Water soluble sdz-rad esters |
AU2292801A (en) | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
US6899731B2 (en) | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
JP2003519655A (ja) | 2000-01-14 | 2003-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | リンパ増殖症候群の緩和および阻害のためのo−メチル化ラパマイシン誘導体 |
US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
GB0005257D0 (en) | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
US20020013335A1 (en) | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
ATE278421T1 (de) * | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
AU2001287157A1 (en) * | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
AU2001296558A1 (en) | 2000-10-03 | 2002-04-15 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
ATE367836T1 (de) | 2000-10-31 | 2007-08-15 | Cook Inc | Beschichtete, implantierbare medizinische geräte |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
WO2002056790A2 (en) * | 2000-12-22 | 2002-07-25 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
PL414997A1 (pl) | 2001-02-19 | 2016-02-29 | Novartis Ag | Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki |
ES2312568T3 (es) | 2001-04-06 | 2009-03-01 | Wyeth | Combinaciones antineoplasicas que comprenden cci-779 (derivado de rapamicina) junto con gemcitabina o fluoruracilo. |
IL158800A0 (en) * | 2001-06-01 | 2004-05-12 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
JP2003330447A (ja) | 2002-05-15 | 2003-11-19 | Mitsubishi Electric Corp | 画像処理装置 |
ES2481671T3 (es) | 2005-11-21 | 2014-07-31 | Novartis Ag | Inhibidores de mTOR en el tratamiento de tumores endocrinos |
RU2609458C2 (ru) | 2011-07-01 | 2017-02-01 | Колопласт А/С | Катетер с баллоном |
EP2606816A1 (en) | 2011-12-22 | 2013-06-26 | Koninklijke Philips Electronics N.V. | A method and system for providing an indication as to the amount of milk remaining in a breast during lactation |
-
2002
- 2002-02-18 PL PL414997A patent/PL414997A1/pl unknown
- 2002-02-18 KR KR1020077022986A patent/KR20070102762A/ko not_active Application Discontinuation
- 2002-02-18 AU AU2002250968A patent/AU2002250968C1/en not_active Expired
- 2002-02-18 SI SI200231092T patent/SI3143995T1/sl unknown
- 2002-02-18 SK SK1038-2003A patent/SK288546B6/sk unknown
- 2002-02-18 EP EP14164259.5A patent/EP2783686B1/en not_active Revoked
- 2002-02-18 PT PT101749851T patent/PT2269604T/pt unknown
- 2002-02-18 DK DK16186041.6T patent/DK3143995T3/en active
- 2002-02-18 SK SK902019A patent/SK288834B6/sk unknown
- 2002-02-18 LT LTEP14164565.5T patent/LT2762140T/lt unknown
- 2002-02-18 CN CN201410469536.8A patent/CN104274442A/zh active Pending
- 2002-02-18 CZ CZ2005-91A patent/CZ200591A3/cs not_active IP Right Cessation
- 2002-02-18 DK DK10174985.1T patent/DK2269604T3/en active
- 2002-02-18 CA CA2438504A patent/CA2438504C/en not_active Expired - Lifetime
- 2002-02-18 SI SI200231056T patent/SI2269603T1/sl unknown
- 2002-02-18 US US10/468,520 patent/US8410131B2/en active Active
- 2002-02-18 CZ CZ2019-248A patent/CZ309247B6/cs not_active IP Right Cessation
- 2002-02-18 MX MX2014014346A patent/MX368013B/es unknown
- 2002-02-18 ES ES10174983.6T patent/ES2543383T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES18155724T patent/ES2744377T3/es not_active Expired - Lifetime
- 2002-02-18 CN CNA028068440A patent/CN1551767A/zh active Pending
- 2002-02-18 EP EP14164565.5A patent/EP2762140B1/en not_active Revoked
- 2002-02-18 ES ES16186041T patent/ES2705016T3/es not_active Expired - Lifetime
- 2002-02-18 RU RU2003127391/15A patent/RU2322981C2/ru active
- 2002-02-18 LT LTEP16186041.6T patent/LT3143995T/lt unknown
- 2002-02-18 EP EP10174985.1A patent/EP2269604B1/en not_active Revoked
- 2002-02-18 CZ CZ2010-473A patent/CZ307940B6/cs not_active IP Right Cessation
- 2002-02-18 JP JP2002565579A patent/JP2004525899A/ja active Pending
- 2002-02-18 PL PL415000A patent/PL415000A1/pl unknown
- 2002-02-18 EP EP18155724.0A patent/EP3342411B1/en not_active Expired - Lifetime
- 2002-02-18 EP EP18155644.0A patent/EP3351246B8/en not_active Revoked
- 2002-02-18 ES ES10174985.1T patent/ES2600304T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES18155644T patent/ES2728739T3/es not_active Expired - Lifetime
- 2002-02-18 DK DK10174983.6T patent/DK2269603T3/en active
- 2002-02-18 EP EP14164561.4A patent/EP2764865A3/en not_active Withdrawn
- 2002-02-18 LT LTEP18155724.0T patent/LT3342411T/lt unknown
- 2002-02-18 EP EP02719864A patent/EP1363627A2/en not_active Withdrawn
- 2002-02-18 SI SI200231078A patent/SI2269604T1/sl unknown
- 2002-02-18 EP EP16186041.6A patent/EP3143995B1/en not_active Expired - Lifetime
- 2002-02-18 PL PL414996A patent/PL231418B1/pl unknown
- 2002-02-18 CZ CZ20032209A patent/CZ303611B6/cs not_active IP Right Cessation
- 2002-02-18 PT PT18155724T patent/PT3342411T/pt unknown
- 2002-02-18 ES ES14164259.5T patent/ES2640787T3/es not_active Expired - Lifetime
- 2002-02-18 WO PCT/EP2002/001714 patent/WO2002066019A2/en active Application Filing
- 2002-02-18 EP EP20100174983 patent/EP2269603B1/en not_active Revoked
- 2002-02-18 DK DK18155644.0T patent/DK3351246T3/da active
- 2002-02-18 PL PL02363918A patent/PL363918A1/xx not_active IP Right Cessation
- 2002-02-18 LT LTEP18155644.0T patent/LT3351246T/lt unknown
- 2002-02-18 SK SK50003-2016A patent/SK288524B6/sk unknown
- 2002-02-18 LT LTEP10174985.1T patent/LT2269604T/lt unknown
- 2002-02-18 CN CN201410286316.1A patent/CN104116738A/zh active Pending
- 2002-02-18 CN CN201410286300.0A patent/CN104083365A/zh active Pending
- 2002-02-18 SI SI200231088A patent/SI2762140T1/sl unknown
- 2002-02-18 PT PT101749836T patent/PT2269603E/pt unknown
- 2002-02-18 SI SI200231097T patent/SI3342411T1/sl unknown
- 2002-02-18 NZ NZ527692A patent/NZ527692A/en not_active IP Right Cessation
- 2002-02-18 SI SI200231094T patent/SI3351246T1/sl unknown
- 2002-02-18 DK DK14164565.5T patent/DK2762140T3/en active
- 2002-02-18 DK DK18155724.0T patent/DK3342411T3/da active
- 2002-02-18 PT PT141645655T patent/PT2762140T/pt unknown
- 2002-02-18 SK SK5011-2005A patent/SK288545B6/sk unknown
- 2002-02-18 PT PT181557224T patent/PT3345602T/pt unknown
- 2002-02-18 BR BR0207378-1A patent/BR0207378A/pt not_active Application Discontinuation
- 2002-02-18 SK SK50008-2016A patent/SK288630B6/sk unknown
- 2002-02-18 CA CA2994779A patent/CA2994779C/en not_active Expired - Lifetime
- 2002-02-18 KR KR1020037010870A patent/KR100695846B1/ko active IP Right Review Request
- 2002-02-18 ES ES14164565.5T patent/ES2629317T3/es not_active Expired - Lifetime
- 2002-02-18 CA CA2860306A patent/CA2860306C/en not_active Expired - Lifetime
- 2002-02-18 CZ CZ2018211A patent/CZ309178B6/cs not_active IP Right Cessation
- 2002-02-18 CN CNB2005100554588A patent/CN1296043C/zh not_active Ceased
- 2002-02-18 IL IL15742502A patent/IL157425A0/xx unknown
- 2002-02-18 PL PL409579A patent/PL409579A1/pl unknown
- 2002-02-18 ES ES18155722T patent/ES2921798T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP18155722.4A patent/EP3345602B1/en not_active Expired - Lifetime
- 2002-02-18 KR KR1020057017585A patent/KR20050095906A/ko not_active Application Discontinuation
- 2002-02-18 MX MXPA03007418A patent/MXPA03007418A/es active IP Right Grant
- 2002-02-18 HU HU0303271A patent/HUP0303271A3/hu not_active Application Discontinuation
- 2002-02-18 EP EP18181342.9A patent/EP3406249A1/en not_active Withdrawn
- 2002-02-18 PT PT18155644T patent/PT3351246T/pt unknown
- 2002-02-18 PT PT16186041T patent/PT3143995T/pt unknown
- 2002-02-19 TW TW095103554A patent/TW200626151A/zh unknown
- 2002-02-19 TW TW091102797A patent/TWI334350B/zh not_active IP Right Cessation
-
2003
- 2003-08-14 IL IL157425A patent/IL157425A/en active IP Right Grant
- 2003-08-18 NO NO20033651A patent/NO333105B1/no not_active IP Right Cessation
- 2003-08-19 MX MX2019010879A patent/MX2019010879A/es unknown
-
2004
- 2004-04-15 HK HK11101880.8A patent/HK1146245A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK14110193.8A patent/HK1197723A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109527.3A patent/HK1250018B/zh not_active IP Right Cessation
- 2004-04-15 HK HK11101882.6A patent/HK1146247A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109752.9A patent/HK1250336B/zh not_active IP Right Cessation
- 2004-04-15 HK HK14112655.5A patent/HK1198946A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109528.2A patent/HK1250019A1/zh not_active IP Right Cessation
-
2005
- 2005-03-01 RU RU2005105664/15A patent/RU2325906C2/ru active
-
2006
- 2006-11-16 RU RU2006140514/15A patent/RU2445093C2/ru not_active IP Right Cessation
-
2007
- 2007-08-06 JP JP2007204409A patent/JP2007284454A/ja active Pending
-
2009
- 2009-11-16 IL IL202155A patent/IL202155A/en active IP Right Grant
-
2011
- 2011-09-22 RU RU2011138835/15A patent/RU2483727C1/ru active
-
2012
- 2012-02-23 US US13/403,474 patent/US20130059877A1/en not_active Abandoned
- 2012-02-23 US US13/403,578 patent/US8436010B2/en not_active Expired - Lifetime
- 2012-04-18 NO NO20120451A patent/NO335134B1/no not_active IP Right Cessation
- 2012-04-26 JP JP2012101519A patent/JP5775022B2/ja not_active Expired - Lifetime
- 2012-05-31 IL IL220096A patent/IL220096A/en active IP Right Grant
- 2012-05-31 IL IL220095A patent/IL220095A/en active IP Right Grant
- 2012-07-11 US US13/546,686 patent/US8778962B2/en not_active Expired - Lifetime
-
2013
- 2013-01-09 NO NO20130045A patent/NO334646B1/no not_active IP Right Cessation
- 2013-04-26 RU RU2013119705A patent/RU2665138C2/ru active
- 2013-05-14 US US13/893,537 patent/US20130253000A1/en not_active Abandoned
- 2013-05-14 US US13/893,589 patent/US20130244951A1/en not_active Abandoned
- 2013-06-27 US US13/928,583 patent/US20130296359A1/en not_active Abandoned
- 2013-06-27 US US13/928,891 patent/US8877771B2/en not_active Expired - Fee Related
- 2013-09-24 RU RU2013143306A patent/RU2659725C2/ru active
- 2013-10-30 IL IL229156A patent/IL229156A/en active IP Right Grant
- 2013-10-30 IL IL229158A patent/IL229158A/en active IP Right Grant
- 2013-10-30 IL IL229157A patent/IL229157A0/en unknown
- 2013-10-30 IL IL229159A patent/IL229159A0/en unknown
- 2013-10-30 IL IL229160A patent/IL229160B/en active IP Right Grant
- 2013-11-19 NO NO20131547A patent/NO336581B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131546A patent/NO336110B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131545A patent/NO336428B1/no not_active Application Discontinuation
- 2013-11-19 NO NO20131544A patent/NO336208B1/no not_active IP Right Cessation
- 2013-12-19 US US14/134,419 patent/US20140105895A1/en not_active Abandoned
-
2014
- 2014-05-02 JP JP2014095034A patent/JP5873128B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114297A patent/JP5879391B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114296A patent/JP2014208657A/ja not_active Withdrawn
-
2015
- 2015-03-18 NO NO2015010C patent/NO2015010I1/no unknown
- 2015-04-08 JP JP2015079430A patent/JP6333766B2/ja not_active Expired - Lifetime
- 2015-04-09 NO NO20150413A patent/NO20150413L/no not_active Application Discontinuation
- 2015-06-24 NO NO20150831A patent/NO340553B1/no not_active IP Right Cessation
- 2015-07-08 NO NO20150895A patent/NO339240B1/no not_active IP Right Cessation
- 2015-08-13 CY CY20151100711T patent/CY1116616T1/el unknown
- 2015-11-17 LU LU92880C patent/LU92880I2/xx unknown
- 2015-11-19 CY CY2015044C patent/CY2015044I2/el unknown
-
2016
- 2016-06-28 US US15/195,018 patent/US20160303092A1/en not_active Abandoned
- 2016-07-29 JP JP2016149701A patent/JP6310970B2/ja not_active Expired - Lifetime
- 2016-08-24 NO NO20161348A patent/NO340924B1/no not_active IP Right Cessation
- 2016-10-21 CY CY20161101060T patent/CY1118316T1/el unknown
- 2016-11-23 LU LU93320C patent/LU93320I2/fr unknown
- 2016-11-28 LT LTPA2016035C patent/LTC2269604I2/lt unknown
- 2016-12-20 CY CY2016047C patent/CY2016047I1/el unknown
-
2017
- 2017-01-06 JP JP2017001065A patent/JP6383814B2/ja not_active Expired - Lifetime
- 2017-02-20 IL IL250676A patent/IL250676B/en active IP Right Grant
- 2017-03-19 IL IL251270A patent/IL251270B/en active IP Right Grant
- 2017-05-16 NO NO20170803A patent/NO343599B1/no not_active IP Right Cessation
- 2017-06-22 CY CY20171100668T patent/CY1119029T1/el unknown
-
2018
- 2018-02-08 JP JP2018021354A patent/JP6349476B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021353A patent/JP6349475B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021352A patent/JP6349474B2/ja not_active Expired - Lifetime
- 2018-05-31 IL IL259724A patent/IL259724B/en unknown
- 2018-06-08 RU RU2018121314A patent/RU2018121314A/ru not_active Application Discontinuation
- 2018-07-06 JP JP2018129096A patent/JP2018168188A/ja not_active Withdrawn
- 2018-07-30 RU RU2018127821A patent/RU2018127821A/ru not_active Application Discontinuation
-
2019
- 2019-01-10 CY CY20191100021T patent/CY1121314T1/el unknown
- 2019-03-04 NO NO20190290A patent/NO20190290A1/no not_active Application Discontinuation
- 2019-06-04 CY CY2019030C patent/CY2019030I1/el unknown
- 2019-06-04 LU LU00122C patent/LUC00122I2/fr unknown
- 2019-06-04 LT LTPA2019511C patent/LTPA2019511I1/lt unknown
- 2019-06-14 CY CY20191100619T patent/CY1121715T1/el unknown
- 2019-09-03 CY CY20191100925T patent/CY1121983T1/el unknown
- 2019-11-21 CY CY2019043C patent/CY2019043I1/el unknown
- 2019-11-21 LT LTPA2019521 patent/LTPA2019521I1/lt unknown
-
2020
- 2020-02-20 LT LTPA2020503C patent/LTPA2020503I1/lt unknown
- 2020-02-20 CY CY2020005C patent/CY2020005I1/el unknown
- 2020-05-26 JP JP2020091227A patent/JP6904640B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI334350B (en) | Cancer treatment | |
US9610289B2 (en) | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | |
CN101415409B (zh) | 用于治疗癌症的治疗剂的组合 | |
AU2020382379B2 (en) | Methods of treating LSD1-related diseases and disorders with LSD1 inhibitors | |
JP2015145396A (ja) | Brca2活性が低下した癌対象の治療のためのsns−595の使用方法 | |
WO2006081452A2 (en) | Co-administration of perifosine with chemotherapeutics | |
CN101305990B (zh) | Edg受体结合剂在癌症中的应用 | |
NZ617249B2 (en) | Combinations of akt inhibitor compounds and vemurafenib, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |